What’s the current market cap for iRadimed stock?

iRadimed (IRMD) has a market cap of $1.2bn as of June 17, 2026.

What is the P/E ratio for iRadimed stock?

The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 49.62 as of June 17, 2026.

Does iRadimed stock pay dividends?

Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is $1.24 and the yield is 0.88%. iRadimed has a payout ratio of 65.37% on a trailing twelve-month basis.

When is the next iRadimed dividend payment date?

The next iRadimed (IRMD) dividend payment date is unconfirmed.

What is the beta indicator for iRadimed?

iRadimed (IRMD) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy iRadimed stock | $IRMD Share Price

13:30

15:10

16:45

18:25

20:00

About iRadimed

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

Ticker

$IRMD

Sector

Health

Primary listing

NASDAQ

Employees

166

Headquarters

Orlando, United States

Website

www.iradimed.com

iRadimed Metrics

BasicAdvanced

$1.2bn

49.62

$1.83

0.91

$1.24

0.88%

What the Analysts think about iRadimed

Analyst ratings (Buy, Hold, Sell) for iRadimed stock.

Bulls say / Bears say

IRADIMED delivered record Q4 2025 revenue of $22.7 million, up 17% year-on-year, with GAAP diluted EPS rising 25% to $0.50, marking its strongest quarterly performance to date. (IRadimed News)

The board increased the regular quarterly dividend from $0.17 to $0.20 per share for Q4 2025 and approved a special $0.50 per share cash dividend in December 2025, underscoring robust free cash flow and commitment to shareholder returns. (IRadimed News)

A gross margin of 76.84% (ttm) highlights the company’s strong pricing power and operational efficiency in its niche MRI-compatible device market. (Forbes)

Elevated valuation with a trailing P/E of 50.33 and forward P/E of 46.17 implies limited margin of safety if growth slows. (Forbes)

The CEO’s trust sold 7,500 shares under a 10b5-1 plan on May 26 and 27, 2026, which may temper confidence despite the plan context. (The Motley Fool)

Management flagged production challenges and a cautious ramp-up for the next-generation 3870 pump, likely leading to a temporary revenue decline in Q2 2026. (Simply Wall St)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

iRadimed Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

iRadimed Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRMD

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

IRADIMED delivered record Q4 2025 revenue of $22.7 million, up 17% year-on-year, with GAAP diluted EPS rising 25% to $0.50, marking its strongest quarterly performance to date. (IRadimed News)

A gross margin of 76.84% (ttm) highlights the company’s strong pricing power and operational efficiency in its niche MRI-compatible device market. (Forbes)

Elevated valuation with a trailing P/E of 50.33 and forward P/E of 46.17 implies limited margin of safety if growth slows. (Forbes)

The CEO’s trust sold 7,500 shares under a 10b5-1 plan on May 26 and 27, 2026, which may temper confidence despite the plan context. (The Motley Fool)

Management flagged production challenges and a cautious ramp-up for the next-generation 3870 pump, likely leading to a temporary revenue decline in Q2 2026. (Simply Wall St)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

About iRadimed

Ticker

Employees

iRadimed Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about iRadimed

Analyst Ratings

Bulls say / Bears say

iRadimed Financial Performance

Income Statement

iRadimed Earnings Performance

Earnings per share (EPS)

Buy $IRMD

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

iRadimed/$IRMD

About iRadimed

Ticker

Employees

iRadimed Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about iRadimed

Analyst Ratings

Bulls say / Bears say

iRadimed Financial Performance

Income Statement

iRadimed Earnings Performance

Earnings per share (EPS)

Buy $IRMD

Upcoming events

No upcoming events

What’s the current market cap for iRadimed stock?

What is the P/E ratio for iRadimed stock?

Does iRadimed stock pay dividends?

When is the next iRadimed dividend payment date?

What is the beta indicator for iRadimed?

Bulls say / Bears say